Dr. Reddy’s Laboratories has entered into a strategic alliance with Biocodex to market and distribute Biocodex products in the Romanian market. Biocodex has announced the change in partnership and effective October 1, 2015, Dr. Reddy’s has been given the complete rights for promotion and distribution of the Biocodex products across Romania.
Earlier, AKACIA was in partnership with Biocodex for similar distribution pact. With this new collaboration coming into existence, Dr. Reddy’s will aim to develop the access of the Romanian patients to the Rx portfolio including Biocodex's well-known OTC products ENTEROL and OTIPAX.
ENTEROL is the ethical pharmaceutical specialty composed of lyophilised Saccharomyces boulardii living cells in a concentration of 250 mg per capsule, or per sachet registered in Romania in packs of 10 capsules and sachets under the trademark ENTEROL.
OTIPAX is the ethical pharmaceutical specialty presented as an ear drop solution containing phenazone and lidocaine hydrochloride, presented in bottles of 15 ml registered in Romania under the trademark OTIPAX.
Dr. Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1904.65 |
| Dr. Reddys Labs. | 1374.55 |
| Cipla | 1458.45 |
| Zydus Lifesciences | 1141.00 |
| Lupin | 2476.10 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: